Acute Pain News and Research RSS Feed - Acute Pain News and Research

Older adults become more sensitive to pain, study shows

Older adults become more sensitive to pain, study shows

When older relatives complain about their pains, show a little empathy, because new research suggests that as we age, we may all become more sensitive to pain. A small, preliminary University of Florida Health study has suggested for the first time that inflammation may occur more quickly and at a higher magnitude -- and stays around longer -- when older adults experience pain versus when younger adults experience pain. [More]
Study reveals TRPV2 protein as new target for chronic pain, cancer treatments

Study reveals TRPV2 protein as new target for chronic pain, cancer treatments

In a recent paper published in Nature Communications, a group of Case Western University School of Medicine researchers presented their discovery of the full-length structure of a protein named Transient Receptor Potential Vanilloid subtype 2 (TRPV2). [More]
ACB could lead to quicker, safer recovery after total knee arthroplasty

ACB could lead to quicker, safer recovery after total knee arthroplasty

Two commonly used nerve blocks during total knee arthroplasty (TKA) are the adductor canal block (ACB) and femoral nerve block (FNB). ACB appears to preserve quadriceps strength superior to FNB while maintaining adequate postoperative pain control. Improving early functional outcome could lead to a quicker and safer recovery with earlier hospital discharges. [More]
Increased use of PNBs in hip and knee arthroplasty could improve medical outcomes

Increased use of PNBs in hip and knee arthroplasty could improve medical outcomes

The use of peripheral nerve blocks (PNBs) is associated with better medical and economic outcomes in patients receiving hip and knee replacement, according to research being presented at the 41st Annual Regional Anesthesiology and Acute Pain Medicine Meeting later this month. [More]
JINARC (tolvaptan) accepted for use in Scotland for ADPKD treatment

JINARC (tolvaptan) accepted for use in Scotland for ADPKD treatment

From today, people in Scotland with the genetic kidney disease ADPKD could benefit from JINARCĀ® (tolvaptan) following advice issued by the Scottish Medicines Consortium (SMC) for its use in adults with chronic kidney disease (CKD) stages 1-3 at the start of treatment with evidence of rapidly progressing disease. [More]
EMA CHMP considers AcelRx's ARX-04 for acute pain treatment for centralized review

EMA CHMP considers AcelRx's ARX-04 for acute pain treatment for centralized review

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the intended treatment of acute pain, reported that the Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency (EMA) has confirmed that a Marketing Authorization Application (MAA) for ARX-04 may be submitted in the European Union (EU) under the Agency's centralized procedure. [More]
New technology may facilitate early detection of sickle cell disease for infants in developing countries

New technology may facilitate early detection of sickle cell disease for infants in developing countries

Researchers from Seidman Cancer Center at University Hospitals Case Medical Center and Case Western Reserve University School of Medicine presented new research findings this weekend at the 57th Annual Meeting of the American Society of Hematology in Orlando. [More]
AfBPM's second National Summit aims to improve pain management, patient safety

AfBPM's second National Summit aims to improve pain management, patient safety

The Alliance for Balanced Pain Management, a diverse collective of 24 health care advocacy groups, patient organizations, industry representatives and other stakeholders, held its second National Summit on Nov. 12 and 13, 2015, to identify continued ways to support appropriate access to integrated pain management and responsible use of prescription pain medicines with an aim to improve patient safety and reduce abuse. [More]
Advanced pain management fellowship prepares CRNAs to meet needs of Americans with chronic pain

Advanced pain management fellowship prepares CRNAs to meet needs of Americans with chronic pain

As the first program of its kind in the United States, an advanced pain management fellowship prepares Certified Registered Nurse Anesthetists (CRNAs) with the pain management skills necessary to meet the needs of Americans with chronic pain, according to the American Association of Nurse Anesthetists. [More]
Nonmedical use of prescription opioids drops but overdose death rates rise in U.S.

Nonmedical use of prescription opioids drops but overdose death rates rise in U.S.

From 2003 to 2013, the percentage of nonmedical use of prescription opioids decreased among adults in the U.S., while the prevalence of prescription opioid use disorders, frequency of use, and related deaths increased, according to a study in the October 13 issue of JAMA. [More]
FDA awards research grants to boost product development for patients with rare diseases

FDA awards research grants to boost product development for patients with rare diseases

The U.S. Food and Drug Administration today announced it has awarded 18 new research grants totaling more than $19 million to boost the development of products for patients with rare diseases, which affect the lives of nearly 30 million Americans. [More]
AcelRx provides update on Zalviso (sufentanil sublingual tablet system)

AcelRx provides update on Zalviso (sufentanil sublingual tablet system)

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute pain, today provided a regulatory update on Zalviso (sufentanil sublingual tablet system) intended for the management of moderate-to-severe acute pain in adult patients in the hospital setting. [More]
AcelRx Pharmaceuticals initiates ARX-04 Phase 3 study in emergency room patients with acute pain

AcelRx Pharmaceuticals initiates ARX-04 Phase 3 study in emergency room patients with acute pain

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute and breakthrough pain, today announced the initiation of an open-label Phase 3 study (SAP302) of ARX-04 for the treatment of adult patients who present in the emergency room with moderate-to-severe acute pain associated with trauma or injury. [More]
Stony Brook Children's Hospital follows pain management protocols to treat pain in pediatric patients

Stony Brook Children's Hospital follows pain management protocols to treat pain in pediatric patients

Stony Brook Children's Hospital clinicians follow pain management protocols to proactively, preemptively, and consistently treat pain in each and every pediatric patient. Known as the Ouchless Approach to Pediatric Medicine, Margaret McGovern, MD, PhD, Physician-in-Chief, describes it as the cornerstone of treatment for pediatric patients at Stony Brook Children's. [More]
FAU researcher finds unique way to monitor sickle cell disease

FAU researcher finds unique way to monitor sickle cell disease

A researcher from Florida Atlantic University has come up with a unique way to monitor sickle cell disease -- a serious blood disorder -- using a smart phone. With a $166,935 grant from the National Science Foundation, E. (Sarah) Du, Ph.D., assistant professor in the Department of Ocean and Mechanical Engineering in FAU's College of Engineering and Computer Science, and principal investigator, will develop a portable smart sensor and a phone application for patients to analyze and store the results of their blood tests on a smart phone. [More]
PDL BioPharma purchases portion of royalties on expected sales of AcelRx's Zalviso

PDL BioPharma purchases portion of royalties on expected sales of AcelRx's Zalviso

PDL BioPharma, Inc. announced today that it has acquired a portion of the royalties on expected sales of AcelRx Pharmaceuticals Inc.'s Zalviso (sufentanil sublingual tablet system) in the European Union, Switzerland and Australia by its commercial partner, Grunenthal. [More]
AcelRx's ARX-04 meets primary and secondary endpoints in Phase 3 trial

AcelRx's ARX-04 meets primary and secondary endpoints in Phase 3 trial

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that ARX-04 (sufentanil sublingual tablet, 30 mcg) met primary and secondary endpoints in a multi-center, double-blind, placebo-controlled Phase 3 trial (SAP301) designed to study the short-term treatment of patients with moderate-to-severe acute pain following ambulatory abdominal surgery. [More]
Charleston Laboratories begins Phase 1 study on CL-H1T migraine drug candidate

Charleston Laboratories begins Phase 1 study on CL-H1T migraine drug candidate

Charleston Laboratories, Inc., an emerging specialty pharmaceutical company, announced initiation of its second clinical development program with a Phase 1 study on its migraine drug candidate, CL-H1T. [More]

CHMP recommends Zalviso for management of acute post-operative pain in adult patients

AcelRx Pharmaceuticals, Inc. announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency, has adopted a positive opinion for Zalviso (sufentanil sublingual tablets). [More]
Immune Pharmaceuticals amends licensing agreement with Endo Pharmaceuticals

Immune Pharmaceuticals amends licensing agreement with Endo Pharmaceuticals

Immune Pharmaceuticals, Inc. announced today that it has amended its 2003 Licensing Agreement with Endo Pharmaceuticals Inc., a subsidiary of Endo International plc. As a result, Immune will transfer to Endo its previously licensed patents related to the use of topical lidocaine in acute and chronic back pain and Endo will grant Immune a royalty-free, non-exclusive, fully transferable license to those patents. [More]
Advertisement
Advertisement